Zobrazeno 1 - 10
of 265
pro vyhledávání: '"Teresa Moran"'
Autor:
James L Gulley, Elad Sharon, Julius Strauss, Steven P Fling, Anna Wright, Teresa Moran, Kathryn Lurain, Ramya Ramaswami, Thomas S Uldrick, Robert Yarchoan, Maria Gonzalez-Cao, Javier Martinez-Picado, Thomas A Odeny
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background The Food and Drug Administration recommends that people living with HIV (PWH) with a CD4+ T cell count (CD4) ≥350 cells/µL may be eligible for any cancer clinical trial, but there is reluctance to enter patients with lower CD4 counts in
Externí odkaz:
https://doaj.org/article/040ee9ed4fc648b5b5356b0d33884972
Autor:
Carmen Balana, Sara Castañer, Cristina Carrato, Teresa Moran, Assumpció Lopez-Paradís, Marta Domenech, Ainhoa Hernandez, Josep Puig
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
Gliomas are a heterogenous group of central nervous system tumors with different outcomes and different therapeutic needs. Glioblastoma, the most common subtype in adults, has a very poor prognosis and disabling consequences. The World Health Organiz
Externí odkaz:
https://doaj.org/article/0f9ce293924c47539a075523775161b8
Autor:
Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Diz, David Aguiar, Carlos García-Giron, Julia Hidalgo, Carlos Aguado, Jorge García González, Emilio Esteban, Lorenzo Gómez-Aldavarí, Teresa Moran, Oscar Juan, Luís Enrique Chara, Juan L. Marti, Rafael López Castro, Ana Laura Ortega, Elia Martínez Moreno, Juan Coves, Ana M. Sánchez Peña, Joaquim Bosch-Barrera, Amparo Sánchez Gastaldo, Natalia Fernández Núñez, Edel del Barco, Manuel Cobo, Dolores Isla, Margarita Majem, Fátima Navarro, Virginia Calvo
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to descri
Externí odkaz:
https://doaj.org/article/8ebc0e8ffdc84091be87e3c5b709643d
Autor:
Ainhoa Hernandez, Marc Boigues, Eudald Felip, Marc Cucurull, Lucia Notario, Anna Pous, Pere Torres, Marta Benitez, Marina Rodriguez, Bibiana Quirant, Margarita Romeo, Daniel Fuster, Teresa Moran
Publikováno v:
Cancers, Vol 15, Iss 1, p 137 (2022)
Lung cancer patients represent a subgroup of special vulnerability in whom the SARS-CoV-2 infection could attain higher rates of morbidity and mortality. Therefore, those patients were recommended to receive SARS-CoV-2 vaccines once they were approve
Externí odkaz:
https://doaj.org/article/1a0d9cdc3628448fa5a608c384d66889
Autor:
Maria Sala, Ana Laura Ortega Granados, Virginia Calvo de Juan, Teresa Moran, Delvys Rodriguez-Abreu, Rafael López-Castro, Eugenio Cuadrado Albite, María Guirado, Lucía Gómez González, Ana Blasco, Manuel Cobo, Rosario Garcia-Campelo, Joaquim Bosch, José Trigo, Óscar Juan, Carlos Aguado de la Rosa, Manuel Dómine, Juana Oramas, Joaquín Casal-Rubio, Sara Cerezo
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Background Lung cancer is currently the leading cause of cancer death. Despite its high incidence and mortality, there are few studies describing its symptoms at diagnosis broken down by tumour stage and tobacco use. Accordingly, this study was propo
Externí odkaz:
https://doaj.org/article/fb04a993644146dfb25df3c66b954387
Autor:
Andrea Plaja, Teresa Moran, Enric Carcereny, Maria Saigi, Ainhoa Hernández, Marc Cucurull, Marta Domènech
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 24, p 13508 (2021)
Small-cell lung cancer (SCLC) is an aggressive malignancy characterized by a rapid progression and a high resistance to treatments. Unlike other solid tumors, there has been a scarce improvement in emerging treatments and survival during the last yea
Externí odkaz:
https://doaj.org/article/4b80d66cef794109b474af5616f5b036
Autor:
Margarita Majem, Manuel Cobo, Dolores Isla, Diego Marquez-Medina, Delvys Rodriguez-Abreu, Joaquín Casal-Rubio, Teresa Moran-Bueno, Reyes Bernabé-Caro, Diego Pérez-Parente, Pedro Ruiz-Gracia, Marta Marina Arroyo, Luis Paz-Ares
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 7, p 1365 (2021)
Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to
Externí odkaz:
https://doaj.org/article/f45d2a2d6192407abbae8c10032547c9
Autor:
Rafael Rosell, Laia Perez-Roca, Jose Javier Sanchez, Manuel Cobo, Teresa Moran, Imane Chaib, Mariano Provencio, Manuel Domine, Maria Angeles Sala, Ulpiano Jimenez, Pilar Diz, Isidoro Barneto, Jose Antonio Macias, Ramon de Las Peñas, Silvia Catot, Dolores Isla, Jose Miguel Sanchez, Rafael Ibeas, Guillermo Lopez-Vivanco, Juana Oramas, Pedro Mendez, Noemi Reguart, Remei Blanco, Miquel Taron
Publikováno v:
PLoS ONE, Vol 4, Iss 5, p e5133 (2009)
Median survival is 10 months and 2-year survival is 20% in metastatic non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy. A small fraction of non-squamous cell lung cancers harbor EGFR mutations, with improved outcome to gefi
Externí odkaz:
https://doaj.org/article/8df183c3cfa54251ba5c08c80b585cbf
Autor:
William Pao, Paul A. Bunn, Marc Ladanyi, Dora Dias-Santagata, Mark G. Kris, Martin L. Sos, Gregory J. Riely, Wilbur A. Franklin, Steven M. Dubinett, Edward B. Garon, Jeffrey A. Engelman, Hidefumi Sasaki, Yumei Pan, Lynne Berry, Cindy L. Vnencak-Jones, David Ross Camidge, Teresa Moran, Charles M. Rudin, Xi Chen, Christine M. Lovly, Maria E. Arcila, Lecia V. Sequist, Kadoaki Ohashi
Purpose: We sought to determine the frequency and clinical characteristics of patients with lung cancer harboring NRAS mutations. We used preclinical models to identify targeted therapies likely to be of benefit against NRAS-mutant lung cancer cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ac13d672a5a9b37b59ae1ab83a2722a
https://doi.org/10.1158/1078-0432.c.6521325
https://doi.org/10.1158/1078-0432.c.6521325
Autor:
Miquel Taron, Charles L Sawyers, Trever G Bivona, Jose Javier Sanchez, Susana Benlloch, Aurelio Ariza, Jose Luis Mate, Maria Sanchez-Ronco, Jose Miguel Sanchez, Itziar de Aguirre, Cristina Queralt, Bartomeu Massuti, Ruth Porta, Enric Carcereny, Santiago Viteri, Margarita Majem, Noemi Reguart, Rosario Garcia-Campelo, Amelia Insa, Manuel Cobo, Mariano Provencio, Dolores Isla, Felipe Cardenal, Pedro Mendez, Teresa Moran, Clara Mayo, Jordi Bertran-Alamillo, Ana Gimenez-Capitan, Sara Simonetti, Carlota Costa, Miguel Angel Molina, Rafael Rosell
Purpose: Advanced non–small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 months when treated with erlotinib. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69cd84e97790f5009bb9f3de55f4f9ee
https://doi.org/10.1158/1078-0432.c.6520164.v1
https://doi.org/10.1158/1078-0432.c.6520164.v1